Related to Companies Step In to Fill Gap in Enzyme Replacement Therapy for Gaucher’s

• Refocusing on Therapeutic Protein Production in Plants
  Recent contamination issues with Genzyme’s CHO-cell manufacturing has highlighted the advantages of plant-based techniques.
  
• 2009 in Review: Headline-Making Stories in the Biotech Industry
  Even though last year was marred by the economic crash, the life science sector showed significant progress.
  
• Reporting from J.P. Morgan Healthcare Conference
  Drug companies developing companion diagnostics is just one of the trends highlighted at the meeting.
  
• Puerto Rico Blindsides Manufacturers
  Industry is lobbying against new tax rules, expected to raise $6 billion over six years.
  
• 2010 in Review: Biotechnology Highlights
  Gene patenting and ESCs were back in the headlines along with breakthroughs in sequencing, syn bio, and other fields.
  
• Will Antibody Biosimilars See the Light of Day?
  Firms copying innovator therapeutic mAbs face manufacturing and regulatory challenges.
  
• High-Tech Companies Buy Into Biomanufacturing
  Samsung and Fujifilm believe such high-investment diversification will help business.
  
• Massachusetts Sees $2B Construction Boom from the Biopharma Industry
  Growth has been built on academic expertise and fueled by tax breaks.
  
• This Month Last Year: Shire and Thermo Fisher’s Acquisitions and Geron’s hESC Plans
  While Geron’s good news in May 2011 didn’t last long, Shire and Thermo hope their moves strengthen their businesses.
  
• Not Quite 1918, but Flu Still Deadly
  Authorities and manufacturers look ahead to new vaccines and immunization efforts while scrambling to deal with spot shortages.
  
• Dendreon’s $70M Investment in Production Capabilities Could Woo Firms without Similar Expertise
  If cell-based immune therapy Provenge receives FDA sanction, it may corner a large market share and expand the company’s prospects.
  
• Big Pharma Adopting Orphan Drug Strategy
  Potential for profitability in small markets is beginning to lure companies away from the failing blockbluster model.
  
• Genzyme Plant Shutdown Could Mean up to $300M in Lost Sales
  Sales of drugs for Fabry, Gaucher’s, and Pompe diseases will take a hit.